Nektar Therapeutics stock fell 3.70 percent on Nasdaq on October 23, 2026

Published on 10/24/2026 at 19:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler kept a USD 192.00 target on October 22, 2026. Nektar Therapeutics stock fell 3.70 percent to USD 37.22 on Nasdaq.

Price move and analyst targets

Piper Sandler maintained a USD 192.00 target on October 22, 2026.
Nektar Therapeutics reported USD 10.13 million in second-quarter 2026 revenue and a USD 40.62 million net loss.
Nektar Therapeutics stock closed at USD 37.22 on Nasdaq on October 23, 2026, down 3.70 percent from the prior close.
The next earnings report is scheduled for November 5, 2026.

NKTR, US6402683063, Illustration mit AI erstellt.

Nektar Therapeutics (ISIN US6402683063) fell 3.70 percent on Nasdaq on October 23, 2026, closing at USD 37.22. The move came as Piper Sandler maintained a Buy rating and a USD 192.00 price target on October 22, 2026, as reported by Business Insider. Nektar Therapeutics stock was last at USD 37.22 on Nasdaq on October 23, 2026 at 4:00 p.m. ET, down 3.70 percent from the prior close.

Analyst target remains far above price

The Piper Sandler target is USD 154.78 above the October 23 closing price, equivalent to 415.50 percent above the price. Gekko listed 14 firms with targets on October 23, 2026, including 10 Buy ratings, 4 Holds and no Sell ratings. Its average target was USD 133.08.

Price sits near the yearly low

Nektar Therapeutics traded within a 52-week range of USD 33.40 to USD 109.00 on October 23, 2026. The close was USD 3.82, or 11.44 percent, above the low and USD 71.78, or 65.85 percent, below the high. Volume was 469,617 shares, while market value stood at USD 1.1 billion on the same date.

Results date follows second-quarter loss

For the quarter ended June 30, 2026, Nektar reported revenue of USD 10.13 million, down 3.25 percent from the USD 10.47 million estimate, and a net loss of USD 40.62 million. Adjusted and GAAP earnings per share were both a loss of USD 1.23, compared with an estimated loss of USD 2.06, according to Earnings Today on August 13, 2026.

The next earnings report is scheduled for November 5, 2026, after the market closes, according to Earnings Today. The same source lists a consensus estimate of a USD 2.07 loss per share and USD 10.27 million in revenue for that report.

Key figures for Nasdaq investors

Nektar is a clinical-stage biotechnology company focused on medicines for immune-mediated diseases. Its Nasdaq listing gives the November report a clear near-term date, while the latest quarter combines USD 10.13 million in revenue with a USD 40.62 million net loss.

Closing price and trading frame

The October 23 close places the stock 11.44 percent above its 52-week low and 65.85 percent below its 52-week high. The USD 192.00 Piper Sandler target is 415.50 percent above the close.